[Bone targeted therapies: new agents]. / Os et thérapies moléculaires ciblées : nouveaux agents.

ABSTRACT

The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFß, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.